BIOEQUIVALENCE STUDY OF TWO BRANDS OF MELOXICAM TABLETS IN HEALTHY HUMAN PAKISTANI MALE SUBJECTS
|
|
- Jared Flowers
- 6 years ago
- Views:
Transcription
1 Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 68 No. 1 pp. 115ñ119, 2011 ISSN Polish Pharmaceutical Society BIOEQUIVALENCE STUDY OF TWO BRANDS OF MELOXICAM TABLETS IN HEALTHY HUMAN PAKISTANI MALE SUBJECTS MAHMOOD AHMAD 1, GHULAM MURTAZA 2 *, NAVEED AKHTAR 1, FARYAL SIDDIQUE 1 and SHUJAAT ALI KHAN 1 1 Faculty of Pharmacy and Alternative Medicines, the Islamia University of Bahawalpur, Bahawalpur-63100, Pakistan 2 COMSATS Institute of Information Technology, Abbottabad, Pakistan Abstract: Meloxicam is a cyclooxygenase-2, preferential inhibitor non-steroidal anti-inflammatory drug (NSAID) and belongs to an enolic acid (oxicam) class used for the treatment of osteoarthritis and rheumatoid arthritis. The purpose of this single dose randomized cross-over study was to assess bioequivalence of two brands of oral meloxicam tablets (Xobix manufactured by Hilton Pharma (Pvt.) Ltd. as a reference and tablet Melfax by AGP (Pvt.) Ltd. as a test) in 18 healthy male volunteers in local population of Pakistan. The data obtained were subjected to non-compartment model pharmacokinetic analysis. The value of C max calculated in present study was ± µg/ml for reference formulation and ± µg/ml (the mean ± SEM) for test sample. The value of T max was ± h for reference standard and ± h (the mean ± SEM) for test sample. The area under the curve from zero to infinity (AUC 0-72) was ± µg h/ml for reference standard and ± µg h/ml for test sample (the mean ± SEM). The t 1/2 values were ± h and ± h (the mean ± SEM) for reference formulation and for test sample, respectively. The test formulation was found to be bioequivalent to reference formulation based on the pharmacokinetic parameters. Keywords: meloxicam, bioequivalence, non-compartment model Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of rheumatoid arthritis and osteoarthritis. However, gastrointestinal disturbances are the most frequently reported side effects of all NSAIDs, and include dyspepsia, gastric erosion, peptic ulcer formation and perforation, major upper gastrointestinal bleeding, inflammation and permeability changes of the intestine and lower bowel (1, 2). Consequently, there is a considerable need for a clinically effective NSAID with an improved safety profile, especially in terms of gastrointestinal side effects. Meloxicam is an enolcarboxamide non-steroidal anti-inflammatory drug with a selective inhibition of cyclooxygenase-2 (COX-2) (3, 4). The drug is less likely to adversely affect the cytoprotective function of arachidonic acid metabolites formed by COX-1 in the gastric mucosa or prostaglandin (PGE 2 ) in the kidney. In a global analysis of studies conducted with meloxicam in patients with rheumatoid arthritis and osteoarthritis, this drug has displayed a favorable gastrointestinal profile, compared to NSAIDs, e.g., piroxicam, naproxen and diclofenac (5ñ7). Meloxicam has bioavailability of 89% after oral administration, is strongly bound to plasma proteins and its half life (t 1/2 ) is 20ñ24 h which allow once daily administration. Meloxicam is nearly completely metabolized and undergoes excretion with approximately half the administered dose eliminated renally, with the remainder excreted in feces (8). The time to reach maximum concentration (T max ) after a 7.5 mg dose under fasted and fed conditions ranged from 4ñ5 h and 5ñ6 h, respectively. If the dose is increased to 30 mg, T max will be prolonged to 9ñ11 h (3, 9). Chemical structure of meloxicam is shown in Figure 1. In Pakistan, yet no study has been conducted on bioequivalence of meloxicam. Consequently, it was very important to conduct the pharmacokinetics and bioavailability studies of meloxicam in the local population. This project was therefore designed to determine the bioequivalence parameters of meloxi- * Corresponding author: ma786_786@yahoo.com; phone: ; fax:
2 116 MAHMOOD AHMAD et al. Table 1. Two way crossover design Treatment Group Period 1 Period 2 I A B II B A Figure 1. Chemical structure of meloxicam cam in domestic situation to ensure the rational usage and safety of this valuable medicinal agent. EXPERIMENTAL Chemicals and Reagents Meloxicam was gifted by AGP, Pakistan. Methanol (HPLC grade), o-phosphoric acid (85%) and hydrochloric acid were purchased from Merck, Germany. Di-sodium hydrogen phosphate was purchased from Riedel-de-Haen, England. All other chemicals and solvents were of analytical grade and used without any further purification. Methods The study was an open, single dose, cross-over complete two period of treatment dosing. Written informed consent was obtained from each subject before commencement of study. Eighteen healthy human male volunteers (age limit 20ñ26 years and body weight range 63ñ87 kg) were scheduled to participate in the study. Each volunteer received single dose of meloxicam (15 mg orally) separated by 2- week washout period. After dosing, serial blood samples were collected for a period of 72 h. Plasma was harvested and analyzed for meloxicam by a modified HPLC method. Formulations Test: Melfax Æ (meloxicam) 15 mg tablets, AGP, Karachi-Pakistan. Reference:Xobix Æ (meloxicam) 15 mg tablets, Hilton Pharma, Karachi- Pakistan. Experimental design The ethics of study was approved by the Board of Advanced Studies and Research, the Islamia University of Bahawalpur, Pakistan. Randomized two way cross over design was adopted for the study as given in Table 1. The volunteers were divided into two groups, 9 in each. The four volunteers of one group received single oral dose of 15 mg of meloxicam tablets (Xobix Æ, Hilton Pharma as a reference product designated as A), whereas the other four received 15 mg of meloxicam tablets (Melfax Æ, AGP Pvt. as a test product designated as B) in the treatment at first period. In the second period, reverse of the first period was administered. The single dose drug regimen was administered on an empty stomach and volunteers were housed at the study center from 1 h before to 72 h after the dosing. Each volunteer was instructed to fast overnight prior to the treatment visit. The volunteers were allowed to drink water at libitum. Each volunteer was provided with standardized breakfast two hours after the dosing. They were also provided the lunch and evening refreshment. A washout period of 14 days was allowed before the start of the second period. Sample collection A 20-gauge venous brannula was inserted into forearm for collection of blood samples. A blood sample was collected before drug was given (zero time) and then at 0.5, 1.0, 2.0, , 6.0, 8.0, 12.0, 24.0, 36.0, 48.0, 60.0 and 72.0 hours after dosing of meloxicam tablets (10). A 5 ml blood sample was collected each time. Blood samples were centrifuged at 3500 rpm for 10 min and plasma was collected and separated into labeled vials. The plasma samples were kept frozen at ñ20 O C until analysis (11). Extraction procedure Extraction procedure was comprising of precipitation method. In extraction procedure, 1 ml of plasma sample was in glass centrifuge tube and 100 µl of 1 M HCl was added. Protein was precipitated out and vortex mixed for one minute then centrifuged at 4000 rpm for 20 min. Supernatant layer was taken and filtered through 0.45 µm Millipore filter, evaporated under the stream of nitrogen at ambient temperature, then reconstituted with 100 µl of the mobile phase and 20 µl were injected on the column for analysis (11).
3 Bioequivalence study of two brands of meloxicam tablets in healthy human male subjects 117 High performance liquid chromatography (HPLC) Analysis was performed by using Perkin Elmer Liquid Chromatograph, with a pump series 200 and Perkin Elmer UV detector set at 346 nm. A reverse phase system was used consisting of C 18 column (150 mm 5 µm particle size 4.6 mm I.D.). The mobile phase consisted of methanol : phosphate buffer (50 mm) (60:40, v/v). The ph of mobile phase was adjusted with ortho-phosphoric acid (85%) to 3.5 and the phase was degassed by passing nitrogen gas for about 2ñ3 min. The mobile phase was pumped at a rate of 1.0 ml/min. Injections of 20 µl volume were injected with a run time of 10 min (12). Safety analysis Health assessment including vital signs, physical examination and clinical laboratory testing was performed before and seven days after study. Subjects were interviewed at the beginning and end of each study period and were monitored throughout of the confinement period to determine any adverse events potentially related to study medication of procedures. Pharmacokinetic analysis Pharmacokinetic analysis was performed by using non-compartmental method of analysis by using Kinetica Æ 4.0 program. Statistical analysis Paired t-test was used to calculate the difference whether significant (p < 0.05) or insignificant (p > 0.05) between the values of the bioparameters of the two different brands of meloxicam, Xobix Æ and Melfax Æ. The confidence level was set at 95%. RESULTS AND DISCUSSION Maximum plasma concentration (C max ) The peak plasma drug concentration C max represents maximum plasma drug concentration obtained after oral administration of drug. In the present study, the (the mean ± SEM) maximum plasma concentration (C max ) for reference and test product was found to be ± µg/ml and ± µg/ml, respectively. This difference was not significant (p > 0.05) and shows that both the brands were bioequivalent. The value for C max in the present study has been found in good agreement with the previous studies conducted in healthy human volunteers. In these studies conducted in healthy male volunteers (8), maximum plasma concentration (C max ) was 1.72 mg/l with 18.8% coefficient of variation with a single oral dose of 30 mg of capsules. The higher value of C max may be due to higher dose, i.e., 30 mg. The C max reported in another study after a single oral dose of 15 mg in healthy subjects (the mean ± SD) was 1.20 ± 0.24 µg/ml (13). So by calculations of the dose, the value of C max calculated in this study was found similar to that given in the literature. There was statistically non-significant difference (p > 0.05) between the values of C max of both the brands. Time of peak plasma concentration (T max ) The time of peak plasma concentration (T max ) corresponds to the time required to reach maximum drug concentration after drug administration. At T max peak drug absorption occurs and the rate of drug absorption exactly equals to the rate of drug elimination (11). In the present study, T max values of reference product and test product were ± h and ± h, respectively. Statistically non significant difference (p > 0.05) was found in the values of T max of both the brands. These values for T max (the mean ± SEM) are in good agreement with the previously reported values of T max (after a single oral dose of 15 mg in healthy subjects) ± 1.17 h (14), and 5.6 ± 3.2 h (the mean ± SD) (13). Another study (15), after a single oral dose of 15 mg in healthy subjects has reported a value of T max as 6.3 ± 2.6 h and 5.3 ± 2.5 h (the mean ± SD) for test and reference product, respectively. The absolute bioavailability of meloxicam tablets was 89% following a single oral dose of 30 mg. The mean maximum plasma concentration (C max ) was achieved within 4ñ5 h after a 7.5 mg meloxicam tablet taken under fasted conditions, indicating prolonged drug absorption. Area under curve (AUC) Area under the curve (AUC) reflects the total amount of drug that reaches the systemic circulation (11). AUC is directly proportional to the dose of the drug. As dose of the drug increases, AUC also increases. In the present study, the value of AUC 0-72 (the mean ± SEM) for the reference product and test product were ± µg h/ml and ± µg h/ml, respectively. A statistically non significant (p > 0.05) difference was found between the values of AUC 0-72 of both the brands. In a previous study conducted on human volunteers (13), AUC 0-8 (the mean ± SD) was found to be ± 7.06 µg h/ml which is in agreement with the values of AUC in the present study.
4 118 MAHMOOD AHMAD et al. Table 2. Comparison of the mean ± SEM of bioavailability and pharmacokinetic parameters of Xobix Æ -Hilton and Melfax Æ -AGP administered in an oral dose of 15 mg in normal subjects. Parameters Xobix Æ -Hilton Melfax Æ -AGP (the mean ± SEM) (the mean ± SEM) C max (µg/ml) ± ± ns T max (h) ± ± ns AUC 0- (µg h/ml) ± ± ns AUC 0-t (µg h/ml) ± ± ns ns = non significant difference (p < 0.05) t 1/2 (h) ± ± ns Figure 2. Comparison of plasma concentration vs. time profile of Xobix Æ -Hilton and Melfax Æ -AGP plotted on rectangular co-ordinate graph, administered in the oral dose of 15 mg to 8 subjects. Half life (t 1/2 ) It is the time required by a drug to become one half of its original concentration in the plasma (11). In the present study, the plasma half life of reference and test products were ± h and ± h (the mean ± SEM), respectively. A statistically non significant (p > 0.05) difference was found between the values of AUC 0- of both the brands. These values are in agreement with the previous findings of h of meloxicam in healthy subjects after oral dose of 15 mg capsule (16). Another study conducted on healthy volunteers using 30 mg tablet has reported t 1/2 value of 17.5 h (1). A study was also conducted using two different tablets of 15 mg in healthy volunteers. The t 1/2 (the mean ± SEM) reported was ± 1.05 h and ± 1.04 h for both the formulations, respectively (14). The half-lives of both the brands show no difference (p > 0.05) when compared statistically. Comparison of the mean ± SEM of bioavailability and pharmacokinetic parameters of Xobix Æ - Hilton and Melfax Æ -AGP administered in the oral dose of 200 mg in normal subjects is in Table 2 and comparison of plasma concentration versus time profile of Xobix Æ -Hilton and Melfax Æ -AGP plotted on rectangular co-ordinate graph, administered in the oral dose of 15 mg in 8 subjects is presented in Figure 2. The elimination half-life (t 1/2 ) of meloxicam is approximately 20 h. This is reflected in a total plasma clearance (Cl T ) of 0.4ñ0.7 L/kg. Steady-state plasma concentrations are achieved within 3ñ5 days. CONCLUSION The results of reference and test brands showed that both these brands possess almost the same bioavailability and pharmacokinetic parameters. Therefore, on the basis of the values of pharmacokinetic and bioavailability parameters, it can be concluded that both the brands are bioequivalent and can be used as pharmaceutical substitute with each other.
5 Bioequivalence study of two brands of meloxicam tablets in healthy human male subjects 119 REFERENCES 1. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ.: Lancet 26, 711 (1987). 2. Busch U., Heinzel G., Narjes H., Nehmiz G.: J. Clin. Pharmacol. 36, 79 (1996). 3. Noble S., Balfour J.A.: Drugs 51, 424 (1996). 4. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R.: Proc. Natl. Acad. Sci. USA 90, (1993). 5. Engelhardt G., Homma D., Schnitzler C.: Inflamm. Res. 44, 548 (1995). 6. Yocum D., Fleischmann R., Dalgin P., Caldwell J., Hall D., Roszko P.: Arch. Intern. Med. 160, 2947 (2000). 7. Distel M., Mueller C., Bluhmki E., Fries J.: Br. J. Rheumatol. 1, 68 (1996). 8. Turck D., Busch U., Heinzel G., Narjes H.: Arzneimittelforschung 47, 253 (1997). 9. Goei T.H.S., Lund B., Distel M.R., Bluhmki E.: Osteoarthr. Cartil. 5, 283 (1997). 10. Dasandi B., Shivaprakash S.H., Bhat K.M.: J. Pharm. Biomed. Anal. 28, 999 (2002). 11. Shargel L., Yu A.; Applied Biopharmaceutics and Pharmacokinetics. 4 th edn., Appleton & Lange, Stamford, CT Nemutlu E., Sayýn F., Baþcý N.E., Kýr S.: Hacettepe Univ. J. Fac. Pharm. 27, 107 (2007). 13. Ghorab MM, Salam AHM, Sayad EMA, Mekhel MM.: AAPS PharmSciTech. 5, 63 (2004). 14. Jimenez M.G., Hernandez J.A., Angeles A.P., Contreras L., Garcia A., et al.: Biopharm. Drug Dispos. 26, 167 (2005). 15. Rojanasthien N., Thummati P., Kumsorn B.: Chian. Mai. Med. Bull. 44, 91 (2005). 16. Ziegler L.E., Velicitat P., Bluhmki E., Turck D., Scheuerer S., Combe B.: Inflamm. Res. 1, 5 (2001). Received:
Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
Inflamm. res. 50, Supplement 1 (2001) S5 S9 1023-3830/01/01S5-05 $ 1.50+0.20/0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability
More informationShivaprakash a,*, H. Saroj a, K.M. Bhat b
ELSEVER Journal of Pharmaceutical and Biomedical Analysis 28 (2002) 999-1004 JOURNAL OF PHARMACEUTCAL AND BOMEDiCAL ANALYSS wwwelseviercom/locate/jpba 1 LC determination Short Communication and pharmacokinetics
More informationPHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES PHARMACOKINETIC INTERACTION OF MOXIFLOXACIN AND
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES PHARMACOKINETIC INTERACTION OF MOXIFLOXACIN AND MELOXICAM FOLLOWING INTRAMUSCULAR ADMINISTRATION IN RATS KA Sadariya, AK Gothi,
More informationSpecific and Simple HPLC Assay of Ecofriendly Meloxicam in Pharmaceutical Formulations K.T. Mahmood 1, B.Khan 2, M. Ashraf 3 and I. U.
Specific and Simple HPLC Assay of Ecofriendly Meloxicam in Pharmaceutical Formulations K.T. Mahmood 1, B.Khan 2, M. Ashraf 3 and I. U.Haq 4 1 DTL,Health Department Punjab, Lahore, 2 Lahore College for
More informationDISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES AFTER INTRAVENOUS ROUTE
Wayamba Journal of Animal Science ISSN: 2012-578X; P322 - P326, 2012 First Submitted May 04, 2012; Number 1337248676 DISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationPharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers
R Iranian Journal of Pharmaceutical Sciences Summer 2006: 2(3): 129-136 www.ijps.ir Original Article Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension
More informationSPECTROPHOTOMETRIC ESTIMATION OF MELOXICAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS
SPECTROPHOTOMETRIC ESTIMATION OF MELOXICAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS B.DHANDAPANI, S.ESWARA MURALI, N. SUSRUTHA, RAMA SWETHA, S K. SONIA RANI, T. SARATH BABU, G.V. SEETHARAMANJANEYULU,
More informationPharmacokinetics and tolerability of meloxicam after i.m. administration
Br J Clin Pharmacol 1996; 41: 135-139 Pharmacokinetics and tolerability of meloxicam after i.m. administration H. NARJES, D. TURCK, U. BUSCH, G. HEINZEL & G. NEHMIZ Human Pharmacology Centre and Department
More informationA Simple Sample Preparation with HPLC UV Method for Estimation of Amlodipine from Plasma: Application to Bioequivalence Study
22 The Open Chemical and Biomedical Methods Journal, 2008, 1, 22-27 Open Access A Simple Sample Preparation with HPLC UV Method for Estimation of Amlodipine from Plasma: Application to Bioequivalence Study
More informationAdverse Effects of Anti-Inflammatory Drugs:
Non-Steroidal anti-inflammatory drug (NSAIDs) are widely used to provide effective anti-inflammatory and analgesic therapy for patients with arthritis. However, they are associated with a high incidence
More informationIsocratic Reverse Phase High Performance Liquid Chromatographic Estimation of Ramipril and Amlodipine in Pharmaceutical Dosage Form
Isocratic Reverse Phase High Performance Liquid Chromatographic Estimation of Ramipril and Amlodipine in Pharmaceutical Dosage Form Manikanta Kumar. A, P. Vijay Kumar *, Mahesh Nasare, Venkateswar Rao,
More informationPharma Research Library. 2013, Vol. 1(1):19-29
Available online at www.pharmaresearchlibrary.com Pharma Research Library International Journal of Current Trends in Pharmaceutical Research 2013, Vol. 1(1):19-29 Pharma Research Library Method development
More informationUltra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE
Ultra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE Matthew Trass, Philip J. Koerner and Jeff Layne Phenomenex, Inc., 411 Madrid Ave.,Torrance, CA 90501 USA PO88780811_L_2 Introduction
More informationDetermination of ofloxacin in bulk drug and pharmaceutical dosage form by high performance liquid chromatography method
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (10):188-192 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationConcentration of Enrofloxacin Residue from Tilapia (Oreochromis niloticus) Muscular That Infected by Aeromonas salmonicida
Journal of Agricultural Science and Technology A 4 (2014) 750-754 Earlier title: Journal of Agricultural Science and Technology, ISSN 1939-1250 doi: 10.17265/2161-6256/2014.09.005 D DAVID PUBLISHING Concentration
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationDETERMINATION OF ACTIVE SUBSTANCES IN MULTICOMPONENT VETERINARY PREPARATIONS OF ANTIPARASITIC ACTION BY HPLC METHOD
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 67 No. 5 pp. 463ñ468, 2010 ISSN 0001-6837 Polish Pharmaceutical Society DETERMINATION OF ACTIVE SUBSTANCES IN MULTICOMPONENT VETERINARY PREPARATIONS OF
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationBioconversion of meloxicam by bacteria
African Journal of Biotechnology Vol. 8 (15), pp. 3610-3614, August, 2009 Available online at http://www.academicjournals.org/ajb ISSN 1996-0786 2009 Academic Journals Full Length Research Paper Bioconversion
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationDevelopment and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker
Development and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker Richa Sah* and Saahil Arora 1. ISF College of Pharmacy, Moga, Punjab, India
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationAMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)
February 2018 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft
More informationDEVELOPMENT AND VALIDATION OF HPLC/UV METHOD FOR DETERMINATION OF MELOXICAM IN HUMAN PLASMA AND APPLICATION IN PHARMACOKINETIC STUDIES
Innovare Academic Sciences International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 7, Issue 1, 2015 Original Article DEVELOPMENT AND VALIDATION OF HPLC/UV METHOD FOR DETERMINATION
More informationCompliance. Should you have any questions, please contact Praveen Pabba, Ph.D., ( or
Doxycycline Hyclate Delayed-Release Tablets Type of Posting Revision Bulletin Posting Date 28 Jul 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance
More informationA VALIDATED HPLC-ASSAY FOR THE DETERMINATION OF MELOXICAM IN PRESENCE OF ITS DEGRADATION PRODUCTS
Sc!entia Pharmaceutica (Sci. Pharm.) 72, 213-220 (2004) 21 3 O Osterreichische Apotheker-Verlagsgesellschaft m. b. H., Wien, Printed in Austria A VALIDATED HPLC-ASSAY FOR THE DETERMINATION OF MELOXICAM
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. SUMMARY OF THE DOSSIER Rheumocam is a generic medicinal product as defined in Article 13(2) (b) of Directive 2001/82/EC, as amended by Directive 2004/28/EC. The reference veterinary
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationMulti-residue Method II for Veterinary Drugs by HPLC (Animal and Fishery Products)
Multi-residue Method II for Veterinary Drugs by HPLC (Animal and Fishery Products) 1. Analytes See Table 8. 2. Instruments High performance liquid chromatograph-photodiode array detector (HPLC-DAD) High
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE AND IRBESARTAN
Indexed in Cite Factor - Directory of International Research Journals in association with leading Universities DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE
More informationCopyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere
More informationEffect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population
Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population M. Zhang, Y. Yang, G. Zhao, X. Di, L. Xu, N. Jiang, J. Xu and X. Xu Department of Pharmacology, the Military
More informationKinetic Studies of Enrofloxacin after Intravenous Administration in Yak
Kinetic Studies of Enrofloxacin after Intravenous Administration in Yak Sanjib Khargharia*, Chandana Choudhury Barua**, H.N. Khanikar**, P. Mohan** * Clintox Bioservices, S.P. Biotech Park, Shameerpet,
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More informationCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com
More informationHPLC method for simultaneous determination of Albendazole metabolites in plasma
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(11): 860-865 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 HPLC method for simultaneous determination of
More informationDetermination of Amlodipine in Rat Plasma by UV Spectroscopy
Determination of Amlodipine in Rat Plasma by UV Spectroscopy P. Srinivasulu 1*, B.K. Gowthami 2, T.N.V. Ganesh Kumar 1, D. Surya Narayana Raju 1, S. Vidyadhara 1 1 Chebrolu Hanumaiah Institute of Pharmaceutical
More informationProviding Constant Analgesia with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S19 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationC 22 H 28 FNa 2 O 8 Pıı516.4
SIMULTANEOUS DETERMINATION OF DEXAMETHASONE SODIUM PHOSPHATE AND CHLORAMPHENICOL IN OPHTHALMIC SOLUTIONS W.A. Shadoul, E.A. Gad Kariem, M.E. Adam, K.E.E. Ibrahim* Department of Pharmaceutical Chemistry,
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationJournal of Global Trends in Pharmaceutical Sciences
An Elsevier Indexed Journal ISSN-2230-7346 Journal of Global Trends in Pharmaceutical Sciences A NEW IMPROVED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE AND
More informationDevelopment of Analytical Methods for the Determination of Flunixin and Phenylbutazone Drug Residues in Edible Bovine Tissues
Development of Analytical Methods for the Determination of Flunixin and Phenylbutazone Drug Residues in Edible Bovine Tissues Philip Asea, John Patterson, & Joe Boison CVDR, Health of Animals Laboratory,
More informationMETHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF OFLOXACIN AND ORNIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC
METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF OFLOXACIN AND ORNIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC B.Dhandapani *1, N.Thirumoorthy 2, Shaik Harun Rasheed 3, M.Rama kotaiah 3
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationIJCBS, 10(2016): International Journal of Chemical and Biochemical Sciences (ISSN )
IJCBS, 10(2016):10-15 International Journal of Chemical and Biochemical Sciences (ISSN 2226-9614) Journal Home page: www.iscientific.org/journal.html International Scientific Organization Quantification
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More informationOral pharmacokinetics of fenbendazole in llamas, South American Camelids
Small Ruminant Research 37 (2000) 209±214 Oral pharmacokinetics of fenbendazole in llamas, South American Camelids Earnest Beier III a, Terry W. Lehenbauer b, Subbiah Sangiah a,* a Department of Anatomy,
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationNSAIDs Are You Following the Rules?
NSAIDs Are You Following the Rules? As equestrians, we expect a lot from our performance horses. Sometimes pain and inflammation of their joints can happen right before a show or competition. Before administering
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationSIMPLE U.V. SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF OFLOXACIN IN PHARMACEUTICAL FORMULATIONS
Int. J. Chem. Sci.: 8(2), 2010, 983-990 SIMPLE U.V. SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF OFLOXACIN IN PHARMACEUTICAL FORMULATIONS C. SOWMYA *, Y. PADMANABHA REDDY, J. RAVINDRA REDDY, M. SIVA
More informationShould you have any questions, please contact Edith Chang, Ph.D., Senior Scientific Liaison ( or
Amlodipine and Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 26 Oct 2018 To Be Determined, Revision Bulletin Expert Committee Chemical Medicines Monographs 2 In
More informationStart of new generation of NSAIDs?
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Start of new generation of NSAIDs? Author : Peter Lees Categories : Vets Date : May 16, 2011 Peter Lees discusses development
More informationDeptt of Pharma Science SGRR ITS Patel Nagar, Dehradun (UK)
METHOD DEVELOPMENT AND ITS VALIDATION FOR SIMULTANEOUS ESTIMATION OF ATORVASTATIN AND AMLODIPINE IN COMBINATION IN TABLET DOSAGE FORM BY UV SPECTROSCOPY, USING MULTI-COMPONENT MODE OF ANALYSIS V. Juyal
More informationTamboli Ashpak Mubarak et al. IRJP 2 (8)
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 8407 Available online http://www.irjponline.com Research Article DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR SIMULTANEOUS DETERMINATION
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationValidation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC
Sahoo et al. SpringerPlus 2014, 3:95 a SpringerOpen Journal RESEARCH Validation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC Nalini Kanta Sahoo
More informationVALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM IN BULK AND PHARMACEUTICAL FORMULATION
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article VALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ATORVASTATIN
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Acticam 1.5
More informationInternational Journal of Pharmaceutical Research & Analysis
13 International Journal of Pharmaceutical Research & Analysis e-issn: 2249 7781 Print ISSN: 2249 779X www.ijpra.com RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationPHARMACOKINETIC VARIATIONS OF OFLOXACIN IN NORMAL AND FEBRILE RABBITS
PHARMACOKINETIC VARIATIONS OF OFLOXACIN IN NORMAL AND FEBRILE RABBITS M. AHMAD, H. RAZA, G. MURTAZA AND N. AKHTAR Department of Pharmacy, Faculty of Pharmacy and Alternative Medicines, The Islamia University
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationNovel RP-HPLC Method Development and Validation of Meloxicam Suppository
Original Article Novel RP-HPLC Method Development and Validation of Meloxicam Suppository Sufiyan Ahmad 1 *, Sharma Deepika 1, Patil Amol 1, Warude Kapil 1, Md. Rageeb Md.Usman 2 1 Department of Quality
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationPublic Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)
Public Assessment Report Scientific discussion Amlodipin Accord (amlodipine besilate) SE/H/842/01-02/MR This module reflects the scientific discussion for the approval of Amlodipin Accord 5 mg and 10 mg
More informationDevelopment and validation of HPLC method for simultaneous estimation of Amlodipine besylate and Enalapril maleate in solid dosage form
World Journal of Pharmaceutical Sciences ISS (Print): 2321-3310; ISS (nline): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ riginal
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Novem 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationDetermination, Confirmation and Quantitation of Multi-Class Antibiotic Residues in Milk by UHPLC MS/MS
APPLICATION NOTE Liquid Chromatography/ Mass Spectrometry Authors: Avinash Dalmia PerkinElmer, Inc. Shelton, CT Determination, Confirmation and Quantitation of Multi-Class Antibiotic Residues in Milk by
More informationAsian Journal of Pharmaceutical Research and Development (An International Peer-Reviewed Journal of Pharmaceutical Research and Development)
Asian Journal of Pharmaceutical Research and Development (An International Peer-Reviewed Journal of Pharmaceutical Research and Development) www.ajprd.com ISSN 2320-4850 Research Article METHOD DEVELOPMENT
More informationResearch Paper Design and Characterization of a Parenteral Formulation of Meloxicam
International Journal of Pharmaceutical Sciences and Nanotechnology Volume 3 Issue 1 April June 2010 Research Paper Design and Characterization of a Parenteral Formulation of Meloxicam P.V. Swamy*, Neelima
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationPHARMACOKINETICS OF FLUNIXIN IN BUFFALO CALVES AFTER SINGLE INTRAMUSCULAR ADMINISTRATION. M.M. Gatne*, M.H. Yadav and T.R. Mahale
Original Article Buffalo Bulletin (December 2012) Vol.31 No.4 PHARMACOKINETICS OF FLUNIXIN IN BUFFALO CALVES AFTER SINGLE INTRAMUSCULAR ADMINISTRATION M.M. Gatne*, M.H. Yadav and T.R. Mahale ABSTRACT The
More informationPradhan Prasanna Kumar et al. Int. Res. J. Pharm. 2014, 5 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF FENAC SODIUM AND FLOXACIN IN THEIR
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More informationAmlodipine, Valsartan, and Hydrochlorothiazide Tablets
. Table Interim Revision Announcement Official November 1, 2017 Amlodipine 1 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 2 (Continued) Tablet Strength Nominal Amlodipine/ Nominal Concentra-
More informationVol-3, Issue-4, Suppl-2, Nov 2012 ISSN: Bandi et al PHARMA SCIENCE MONITOR
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES PREPARATION AND CHARACTERIZATION OF NANOPARTICLES FOR DISSOLUTION RATE ENHANCEMENT OF MELOXICAM Bandi Ramesh*, S Parthiban, S
More informationMOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal for The International Pharmacopoeia. (January 2018)
January 2018 DRAFT FOR COMMENT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 MOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationResearch update - medicines for koalas
Sydney School of Veterinary Science istock photo Research update - medicines for koalas Merran Govendir Associate Professor in Veterinary Pharmacology merran.govendir@sydney.edu.au 1 Introduction Who we
More informationNSAIDs: the Past, Present, and Future
NSAIDs: the Past, Present, and Future Resident Seminar - November 2017 Lisanne Gallant, DVM Large Animal Medicine Resident Outline Physiology Review Use in Large Animals Adverse Effects Cases The Future
More informationA Unique Approach to Managing the Problem of Antibiotic Resistance
A Unique Approach to Managing the Problem of Antibiotic Resistance By: Heather Storteboom and Sung-Chul Kim Department of Civil and Environmental Engineering Colorado State University A Quick Review The
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More information